

Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)

**Date:** 08/11/2024

**Location:** Virtual

**Minutes:** Final

<b>Committee members present:</b>		
Adam Firth	Chair	Present for notes 1 – 9
Ramsey Cutress	Topic Adviser	Present for notes 1 – 9
Kwok Leung Cheung	Breast surgeon	Present for notes 1 – 9
Mark Davies	Medical oncologist	Present from partway through item 5
Kay Davies-Crowley	Nurse specialist	Present for notes 1 – 9
Milly Finch	Pharmacist	Present for notes 1 – 9
Tim Robinson	Medical oncologist	Present for notes 1 – 6
Elinor Sawyer	Clinical oncologist	Present for notes 1 – 9
David Talbot	Lay member	Present for notes 1 – 9
Katy Tan	Lay member	Present for notes 1 – 9
Ben Thwaites	Pharmacist	Present for notes 1 – 9

<b>In attendance:</b>		
Sarah Boyce	Senior Technical Analyst	Present for notes 1 - 9
Victoria Carter	Implementation Support Manager	Present for notes 1 - 9
Lindsay Claxton	Health Economics Adviser	Present for notes 1 - 9
Gareth Haman	Senior Guidance Content Designer	Present for notes 1 - 9
Marie Harrisingh	Topic Lead	Present for notes 1 - 9
Yolanda Martinez	Technical Analyst	Present for notes 1 - 9
Adam O'Keefe	Project Manager	Present for notes 1 - 9
Katherine Saxby	Medicines Adviser	Present for notes 1 - 9
Hannah Tebbs	Senior Health Economist	Present for notes 1 - 9

<b>Apologies:</b>	
Rachael Griffin	Lay member
Sadaf Haque	GP
Andrea Heath	Senior Information Specialist, NICE
Adam Storrow	Business Analyst, Resource Impact Assessment, NICE

<b>1. Welcome, introductions and apologies</b>
<p>The Chair welcomed the committee members and NICE attendees to the fourth committee meeting for the Neoadjuvant chemotherapy and ovarian function suppression update to the NICE Early and locally advanced breast cancer: diagnosis and management guideline.</p> <p>The Chair informed the Committee that apologies had been received. These are noted above.</p>
<b>2. Minutes of the previous meeting</b>
<p>The group ratified the minutes of the previous meeting as an accurate reflection of the discussion.</p>
<b>3. Declarations of interest</b>
<p>The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Neoadjuvant chemotherapy and ovarian function suppression.</p> <p>The Chair asked everyone to verbally declare any new interests. No new interests were declared. The Chair and a senior member of the Developer's team noted that no previously declared interests would prevent attendees from fully participating in the meeting.</p>
<b>4 – 5. Review Question 2.2: What is the clinical and cost effectiveness of testicular function suppression combined with aromatase inhibitors compared to tamoxifen or aromatase inhibitors alone in people with ER positive invasive breast cancer who have male reproductive organs?</b>
<p>The Chair introduced NICE Technical Analyst Yolanda Martinez who presented the clinical evidence identified for this review question. The Chair introduced NICE Senior Health Economist Hannah Tebbs who advised the committee that no Health economic evidence had been identified for this review question before discussing costs related to this treatment with the group. The committee discussed the evidence presented and any health inequalities considerations before drafting recommendations.</p>
<b>6. Revisiting earlier recommendations</b>
<p>The Chair introduced NICE Topic Lead, Marie Harrisingh whom revisited with the committee the recommendations drafted at previous meetings to resolve any outstanding queries and update these as necessary.</p>
<b>7. Research recommendations</b>
<p>The Chair reintroduced NICE Topic Lead, Marie Harrisingh who revisited and agreed draft research recommendations and the rationales behind these with the committee.</p>

<b>8. Review of reorganised Guideline with TA incorporation</b>
The group reviewed and agreed the structure of the reorganised full NICE guideline with relevant NICE Technology Appraisals having been incorporated.
<b>9. AOB, Summary and next steps</b>
Adam O’Keefe, NICE Project Manager outlined next steps following the meeting before the Chair thanked the committee for their contributions, summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, the Chair brought the meeting to a close.

**Date of next meeting:** 07/03/2025

**Location of next meeting:** Virtual